about
Severe multisystemic hypersensitivity reaction to carbamazepine including dyserythropoietic anemiaTherapeutic safety monitoring: what to look for and when to look for it.Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions.Carbamazepine-induced thrombocytopenia and carbamazepine-10,11-epoxide: a case report.CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile.Anticonvulsant Use in the Treatment of Bipolar Disorder: A Primer for Primary Care PhysiciansThe role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions.Case report: scurvy in an epileptic child on a ketogenic diet with oral complications.The long-term safety of antiepileptic drugs.Carbamazepine toxicity and poisoning. Incidence, clinical features and management.Carbamazepine side effects in children and adults.Drugs and the periodontium.The medical and surgical management of trigeminal neuralgia.Pharmacotherapy of aggressive behavior.Evaluation of case reports of aplastic anemia among patients treated with felbamate.Fatal aplastic anemia in a patient treated with carbamazepine.A retrospective study of compliance with recommended hematologic monitoring of carbamazepine.Spike-and-wave complexes and seizure exacerbation caused by carbamazepine.Carbamazepine. What physicians should know about its hematologic effects.Evaluation of the mechanisms of antiepileptic drug-related chronic leukopenia.Monitoring for adverse effects of antiepileptic drugs.
P2860
Q28377877-41CD14AF-3CFC-4CD0-91B1-38C3CAB847F9Q33335206-9EC0872E-1F08-4E20-B659-7E26AC2B2365Q33396340-F30A1114-BB33-434D-84A8-7B32823C86B3Q33495527-575F46B2-A192-4AC2-A80F-6A91C77EFF99Q33898107-BC611BBD-F5D2-4FA9-A9B4-575A895E39DFQ35664266-AAD1BC3F-D0D1-43EF-B02B-A799AFEBCD02Q36312078-2EADFDB3-555E-4A5B-9A63-BCE13DA1D8FFQ37269714-9FF61545-B491-4EB5-A6B1-5CE2F32D06FDQ38106856-3ADB7DA4-4A35-4852-83DD-820339F8AB54Q38627226-286784A6-4989-4ABC-AB70-AD312FCD7156Q39484138-9DE60CF3-50AC-4CF7-885F-09D7052DB227Q39627142-C51944F5-A675-4C36-ABBC-263349A510A2Q40541600-30ED761D-C4D7-48B2-8131-E1A8ADF144CFQ41132961-568E6A65-622D-4413-A5AE-D3D27CA59E71Q41760342-1F43CE77-7EFB-4078-A99B-DA7E63665063Q42214920-0BD16BF7-6546-472A-998A-64388E40DD55Q43717571-F0233807-5ADB-4248-AADF-03AC154888DEQ43849919-8B56BA1D-59DC-4BF9-8B36-9F75BFEE19BDQ44433988-9B8DEB49-6C7B-4863-A8CA-4A30CF7E11E7Q51137472-3AA691B7-8CE7-40FC-91BF-CB9D23DBA90FQ51930974-6F9D263B-B355-4FA5-BA6F-631B0C889D46
P2860
description
1982 nî lūn-bûn
@nan
1982 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1982 թվականի մարտին հրատարակված գիտական հոդված
@hy
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
name
Carbamazepine and hematological monitoring.
@ast
Carbamazepine and hematological monitoring.
@en
type
label
Carbamazepine and hematological monitoring.
@ast
Carbamazepine and hematological monitoring.
@en
prefLabel
Carbamazepine and hematological monitoring.
@ast
Carbamazepine and hematological monitoring.
@en
P2860
P356
P1433
P1476
Carbamazepine and hematological monitoring.
@en
P2093
P2860
P304
P356
10.1002/ANA.410110312
P577
1982-03-01T00:00:00Z